Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
NEW YORK, Jan. 08, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Meridian Bioscience, Inc. (NASDAQ:VIVO) from March 25, 2016 through July 13, 2017, inclusive (the “Class Period”) of the important January 16, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Meridian Bioscience investors under the federal securities laws.
To join the Meridian Bioscience class action, go to http://rosenlegal.com/cases-1246.html or call Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendant’s lead tests provide inaccurate results; and (2) as a result, Meridian Bioscience’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1246.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Daniel Sadeh, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Daniel Sadeh, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
